Search

Your search keyword '"De Amicis, D."' showing total 7 results
Start Over Author "De Amicis, D." Publisher biolife
7 results on '"De Amicis, D."'

1. Human amniotic fluid stem cells culture onto titanium screws: a new perspective for bone engineering.

Author

Antonucci I, Pantalone A, De Amicis D, D'Onofrio S, Stuppia L, Palka G, and Salini V

Subjects
Antigens, Differentiation biosynthesis, Bone Screws, Calcification, Physiologic physiology, Cells, Cultured, Female, Humans, Microscopy, Electron, Scanning, Osteoblasts ultrastructure, Stem Cells ultrastructure, Amniotic Fluid cytology, Amniotic Fluid metabolism, Osteoblasts metabolism, Stem Cells metabolism, Tissue Engineering, Titanium
Abstract

The use of titanium plates and screws for osteosynthesis is considered to be an effective treatment for different kinds of fractures in orthopedic surgery. The aim of the present study is to test the ability of titanium screws to promote the growth of osteoblasts obtained from human amniotic fluid stem cells (AFS). Osteoblastic differentiation was assessed by RT-PCR of specific markers such as COL1, ONC, OPN, OCN, OPG, BMP-4 and Runx2. Mineralization was demonstrated by the presence of red depositions. Adherent cells were found to cover the whole surface of titanium screw by Scanning Electron Microscopy (SEM). The result indicates the excellent growth of osteoblasts obtained from amniotic fluid on a titanium surface and could represent an important point in view of a possible therapeutic application of AFS cells.

Published
2009

2. Infections and mast cells.

Author

Felaco P, Toniato E, Castellani ML, Ciampoli C, De Amicis D, Orso C, Cuccurullo C, De Lutiis MA, Patruno A, Speranza L, Felaco M, Caraffa A, Pandolfi F, Antinolfi PL, Cerulli G, Conti F, Fulcheri M, Sabatino G, Conti P, and Shaik Y

Subjects
Animals, Humans, Immunoglobulin E metabolism, Infections metabolism, Infections parasitology, Inflammation Mediators metabolism, Mast Cells metabolism, Receptors, IgE metabolism, Immunoglobulin E immunology, Infections immunology, Inflammation Mediators immunology, Mast Cells immunology, Receptors, IgE immunology
Abstract

Mast cells play a role in various physiological functions: innate and acquired immunity, epithelium remodelling and proliferation, angiogenesis, cancer, inflammation and infections. Mast cells are activated by cross-linking of FcERI molecules, which are involved in the binding of multivalent antigens to the attached IgE molecules, resulting in a variety of responses including the immediate release of potent inflammatory mediators. In addition, mast cell biology consists in the capability to secrete preformed mediators which include biogenic amines and newly synthetized mediators, which include lipid-derived mediators and cytokines. It has been reported that parasite infections induce a systemic immunomodulatory network, including regulatory T cells, pro-inflammatory and anti-inflammatory cytokines, which might play a key role in the allergic phenotype. Here, in this article, we revisited the relationship between mast cells and infections.

Published
2009

3. IL-32: a newly-discovered proinflammatory cytokine.

Author

Felaco P, Castellani ML, De Lutiis MA, Felaco M, Pandolfi F, Salini V, De Amicis D, Vecchiet J, Tete S, Ciampoli C, Conti F, Cerulli G, Caraffa A, Antinolfi P, Cuccurullo C, Perrella A, Theoharides TC, Conti P, Toniato E, Kempuraj D, and Shaik YB

Subjects
Animals, Cell Differentiation, Humans, Immunity, NF-kappa B metabolism, Inflammation Mediators metabolism, Interleukins metabolism
Abstract

IL-32, a newly-discovered proinflammatory cytokine that activates the p38MAPK and NF-kappaB pathways, is an important player in innate and adaptive immune response. IL-32, a cytokine produced mainly by T, natural killer, and epithelial cells induces significant amounts of TNFalpha and MIP-2 and increases the production of both cytokines in a dose-dependent manner. IL-32 has been implicated in inflammatory disorders, mycobacterium tuberculosis infections, inflammatory bowel disease, and influenza A virus infection, as well as in some autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis and Crohn?s disease and in human stomach cancer, human lung cancer and breast cancer tissues. Moreover, it has been reported that IL-32 has pro-inflammatory effects on myeloid cells and causes the differentiation of osteoclast precursors into multinucleated cells expressing specific osteoclast markers. We recently found that human IL-32 has the capacity to provoke histamine release in human-derived cord blood mast cells (HDCBMC), but not in LAD 2 cells nor in rat peritoneal mast cells (RPMC), showing that IL-32 may be specie specific and act more in mature human mast cells (HDCBMC) than in transformed mast cells (LAD 2 cells). Certainly, IL-32 is another potent proinflammatory cytokine, however, the specific role of this newly-discovered protein in the network of cytokine biology remains to be determined.

Published
2009

4. The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator.

Author

Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tete S, Ciampoli C, Conti F, Cerulli G, Caraffa A, Antinolfi P, Theoharides TC, De Amicis D, Perrella A, Cuccurullo C, Boscolo P, and Shaik Y

Subjects
Animals, Asthma immunology, Atherosclerosis immunology, Mice, Interleukin-1 immunology, Interleukins immunology, Mast Cells immunology
Abstract

IL-33, a member of IL-1 family, induces the differentiation of T-cells (depending on the phosphorylation of MAPKs and NF-kB) and is involved in T-cell mediated immune responses. IL-33 is also involved in the production of IL-5, IL-4 and IL-13 and several chemokines. In this editorial we show the importance of IL-33 in allergic diseases and its role as an inflammatory cytokine. In addition, the induction of certain chemokines by IL-33 may candidate this new cytokine as a mediator in inflammatory and autoimmune diseases and may prove to be a therapeutic target for the prevention of these diseases.

Published
2009

5. Effect of a subgingival chlorhexidine chip on the clinical parameters and the levels of alkaline phosphatase activity in gingival crevicular fluid during the non-surgical treatment of periodontitis.

Author

Paolantonio M, Dolci M, Perfetti G, Sammartino G, D' Archivio D, Spoto G, Ciampoli C, De Amicis D, and Tete S

Subjects
Adult, Anti-Infective Agents, Local administration & dosage, Anti-Infective Agents, Local therapeutic use, Chlorhexidine administration & dosage, Delayed-Action Preparations, Gingiva drug effects, Gingiva enzymology, Humans, Middle Aged, Single-Blind Method, Alkaline Phosphatase metabolism, Chlorhexidine therapeutic use, Gingiva metabolism, Periodontitis drug therapy
Abstract

The main therapeutic approaches for inflammatory periodontal diseases include the mechanical treatment of root surfaces. Multi-center clinical trials have demonstrated that the adjunctive use of a chlorhexidine (CHX) chip is effective in improving clinical results compared to scaling and root planing (SRP) alone. However, some recent studies failed to confirm these clinical results, nor have any data been reported regarding the capability of the CHX chip in affecting the activity of alkaline phosphatase (ALP) in the gingival crevicular fluid (GCF). This enzyme has been related to a condition of destructive activity of periodontitis. The aim of this study is to provide further data on the clinical and biochemical effects of CHX chips when used as an adjunct to SRP. Eighty-two systemically healthy patients, aged 31-63, with moderate and advanced periodontitis were recruited from the departments of Periodontology of the University of Chieti. In each patient 2 experimental sites, located in two symmetric quadrants, were chosen with a probing depth of > or = 5 mm and bleeding on probing. The 2 sites were selected randomly at the split-mouth level; control sites received SRP alone, and test sites SRP plus 1 CHX chip. Clinical indices, including probing depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and the ALP activity in GCF were evaluated at baseline and after 6 months. Alkaline phosphatase activity was assayed spectrophotometrically. The PPD and CAL were significantly lower at 6 months as compared to the baseline scores in both treatments (p less than 0.01). The PPD reduction was 2.7 mm in the CHX+SRP group and 1.9 mm in the SRP alone group. The CHX+SRP group showed a significantly greater gain of clinical attachment (mean: 1.4 mm) in comparison with the SRP group (mean: 0.9; p less than 0.05). No differences were observed in the decrease of the percent of BOP-positive sites between the experimental groups. Conversely, the CHX+SRP group underwent a significantly greater decrease (p less than 0.01) of the GCF-ALP activity 6 months after treatment in comparison with the SRP alone group. The adjunctive use of the CHX chip resulted in a significant improvement of pocket reduction and clinical attachment gain as compared with SRP alone. These results were concomitant with a significantly greater reduction of the GCF-ALP activity levels.

Published
2008

6. Capsaicin an irritant anti-inflammatory compound.

Author

Anogianaki A, Negrev NN, Shaik YB, Castellani ML, Frydas S, Vecchiet J, Tete S, Salini V, De Amicis D, De Lutiis MA, Conti F, Caraffa A, and Cerulli G

Subjects
Analgesics pharmacology, Analgesics therapeutic use, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Capsaicin pharmacology, Gastrointestinal Agents pharmacology, Gastrointestinal Agents therapeutic use, Heart Diseases prevention & control, Humans, Irritants pharmacology, Nasal Decongestants pharmacology, Nasal Decongestants therapeutic use, Neoplasms prevention & control, Nervous System Diseases drug therapy, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Capsaicin therapeutic use, Irritants therapeutic use
Published
2007

7. Study on the effectiveness of a nifedipine gel for treatment of Raynaud?s phenomenon.

Author

Foti C, Quaranta D, Pepe ML, Morea G, Mastropasqua D, D'Amore M, Mastrangelo F, Tete S, Grassi FR, Ballini A, Salini V, De Amicis D, Scagliusi P, De Lutiis MA, Caraffa A, and Cerulli G

Subjects
Fingers, Humans, Pain, Nifedipine, Raynaud Disease
Abstract

The aim of this study is to evaluate the efficacy of a nifedipine gel in patients with primary or secondary Raynaud?s phenomenon. Photopletismography was the instrumental examination test used to evaluate recovery time (time necessary for recuperation of normal capillary circulation) in 17 patients with primary or secondary Raynaud?s phenomenon before and after the application of the gel. It emerged that of the 17 patients who used the gel, in 3 cases the recovery time was reduced, in 9 cases the recovery time was cancelled (no spasm occurred), in 5 cases the recovery time was not modified. Therefore, in more than 70 percent of patients the drug had a positive effect. Besides, 50 percent of the patients referred an improvement of the subjective symptomatology with reduction of cooling, torpidity, ache and paresthesias of the fingers. The results obtained, even if related to a restricted number of patients and to a brief interval of time, show the effectiveness of this drug in patients with primary or secondary Raynaud?s phenomenon. We believe that these results, presented here for the first time, are important for investigators involved in the study of Raynaud?s disease.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results